Exploration of the ocular surface infection by SARS-CoV-2 and implications for corneal donation: An ex vivo study.
Adult
Aged
Angiotensin-Converting Enzyme 2
/ metabolism
Animals
COVID-19
/ complications
Cathepsins
/ metabolism
Chlorocebus aethiops
Cornea
/ metabolism
Corneal Diseases
/ virology
Culture Media
Eye Infections, Viral
/ virology
Female
Humans
Male
Middle Aged
Organ Culture Techniques
RNA, Viral
/ metabolism
Receptors, Coronavirus
/ metabolism
SARS-CoV-2
/ physiology
Serine Endopeptidases
/ metabolism
Vero Cells
Virus Replication
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
01
06
2021
accepted:
19
01
2022
entrez:
1
3
2022
pubmed:
2
3
2022
medline:
12
3
2022
Statut:
epublish
Résumé
The risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission through corneal graft is an ongoing debate and leads to strict restrictions in corneas procurement, leading to a major decrease in eye banking activity. The aims of this study are to specifically assess the capacity of human cornea to be infected by SARS-CoV-2 and promote its replication ex vivo, and to evaluate the real-life risk of corneal contamination by detecting SARS-CoV-2 RNA in corneas retrieved in donors diagnosed with Coronavirus Disease 2019 (COVID-19) and nonaffected donors. To assess the capacity of human cornea to be infected by SARS-CoV-2, the expression pattern of SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE-2) and activators TMPRSS2 and Cathepsins B and L in ocular surface tissues from nonaffected donors was explored by immunohistochemistry (n = 10 corneas, 78 ± 11 years, 40% female) and qPCR (n = 5 corneas, 80 ± 12 years, 40% female). Additionally, 5 freshly excised corneas (80 ± 12 years, 40% female) were infected ex vivo with highly concentrated SARS-CoV-2 solution (106 median tissue culture infectious dose (TCID50)/mL). Viral RNA was extracted from tissues and culture media and quantified by reverse transcription quantitative PCR (RT-qPCR) (viral RNA copies) 30 minutes (H0) and 24 hours (H24) after infection. To assess the risk of corneal contamination by SARS-CoV-2, viral RNA was tested by RT-qPCR (Ct value) in both corneas and organ culture media from 14 donors diagnosed with COVID-19 (74 ± 10 years, 29% female) and 26 healthy donors (79 ± 13 years, 57% female), and in organ culture media only from 133 consecutive nonaffected donors from 2 eye banks (73 ± 13 years, 29% female). The expression of receptor and activators was variable among samples at both protein and mRNA level. Based on immunohistochemistry findings, ACE-2 was localized mainly in the most superficial epithelial cells of peripheral cornea, limbus, and conjunctiva, whereas TMPRSS2 was mostly expressed in all layers of bulbar conjunctiva. A significant increase in total and positive strands of IP4 RNA sequence (RdRp viral gene) was observed from 30 minutes to 24 hours postinfection in central cornea (1.1 × 108 [95% CI: 6.4 × 107 to 2.4 × 108] to 3.0 × 109 [1.4 × 109 to 5.3 × 109], p = 0.0039 and 2.2 × 107 [1.4 × 107 to 3.6 × 107] to 5.1 × 107 [2.9 × 107 to 7.5 × 107], p = 0.0117, respectively) and in corneoscleral rim (4.5 × 109 [2.7 × 109 to 9.6 × 109] to 3.9 × 1010 [2.6 × 1010 to 4.4 × 1010], p = 0.0039 and 3.1 × 108 [1.2 × 108 to 5.3 × 108] to 7.8 × 108 [3.9 × 108 to 9.9 × 108], p = 0.0391, respectively). Viral RNA copies in ex vivo corneas were highly variable from one donor to another. Finally, viral RNA was detected in 3 out of 28 corneas (11%) from donors diagnosed with COVID-19. All samples from the 159 nonaffected donors were negative for SARS-CoV-2 RNA. The main limitation of this study relates to the limited sample size, due to limited access to donors diagnosed with COVID-19 and concomitant decrease in the procurement corneas from nonaffected donors. In this study, we observed the expression of SARS-CoV-2 receptors and activators at the human ocular surface and a variable increase in viral RNA copies 24 hours after experimental infection of freshly excised human corneas. We also found viral RNA only in a very limited percentage of donors with positive nasopharyngeal PCR. The low rate of positivity in donors diagnosed with COVID-19 calls into question the utility of donor selection algorithms. Agence de la Biomédecine, PFS-20-011 https://www.agence-biomedecine.fr/.
Sections du résumé
BACKGROUND
The risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission through corneal graft is an ongoing debate and leads to strict restrictions in corneas procurement, leading to a major decrease in eye banking activity. The aims of this study are to specifically assess the capacity of human cornea to be infected by SARS-CoV-2 and promote its replication ex vivo, and to evaluate the real-life risk of corneal contamination by detecting SARS-CoV-2 RNA in corneas retrieved in donors diagnosed with Coronavirus Disease 2019 (COVID-19) and nonaffected donors.
METHODS AND FINDINGS
To assess the capacity of human cornea to be infected by SARS-CoV-2, the expression pattern of SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE-2) and activators TMPRSS2 and Cathepsins B and L in ocular surface tissues from nonaffected donors was explored by immunohistochemistry (n = 10 corneas, 78 ± 11 years, 40% female) and qPCR (n = 5 corneas, 80 ± 12 years, 40% female). Additionally, 5 freshly excised corneas (80 ± 12 years, 40% female) were infected ex vivo with highly concentrated SARS-CoV-2 solution (106 median tissue culture infectious dose (TCID50)/mL). Viral RNA was extracted from tissues and culture media and quantified by reverse transcription quantitative PCR (RT-qPCR) (viral RNA copies) 30 minutes (H0) and 24 hours (H24) after infection. To assess the risk of corneal contamination by SARS-CoV-2, viral RNA was tested by RT-qPCR (Ct value) in both corneas and organ culture media from 14 donors diagnosed with COVID-19 (74 ± 10 years, 29% female) and 26 healthy donors (79 ± 13 years, 57% female), and in organ culture media only from 133 consecutive nonaffected donors from 2 eye banks (73 ± 13 years, 29% female). The expression of receptor and activators was variable among samples at both protein and mRNA level. Based on immunohistochemistry findings, ACE-2 was localized mainly in the most superficial epithelial cells of peripheral cornea, limbus, and conjunctiva, whereas TMPRSS2 was mostly expressed in all layers of bulbar conjunctiva. A significant increase in total and positive strands of IP4 RNA sequence (RdRp viral gene) was observed from 30 minutes to 24 hours postinfection in central cornea (1.1 × 108 [95% CI: 6.4 × 107 to 2.4 × 108] to 3.0 × 109 [1.4 × 109 to 5.3 × 109], p = 0.0039 and 2.2 × 107 [1.4 × 107 to 3.6 × 107] to 5.1 × 107 [2.9 × 107 to 7.5 × 107], p = 0.0117, respectively) and in corneoscleral rim (4.5 × 109 [2.7 × 109 to 9.6 × 109] to 3.9 × 1010 [2.6 × 1010 to 4.4 × 1010], p = 0.0039 and 3.1 × 108 [1.2 × 108 to 5.3 × 108] to 7.8 × 108 [3.9 × 108 to 9.9 × 108], p = 0.0391, respectively). Viral RNA copies in ex vivo corneas were highly variable from one donor to another. Finally, viral RNA was detected in 3 out of 28 corneas (11%) from donors diagnosed with COVID-19. All samples from the 159 nonaffected donors were negative for SARS-CoV-2 RNA. The main limitation of this study relates to the limited sample size, due to limited access to donors diagnosed with COVID-19 and concomitant decrease in the procurement corneas from nonaffected donors.
CONCLUSIONS
In this study, we observed the expression of SARS-CoV-2 receptors and activators at the human ocular surface and a variable increase in viral RNA copies 24 hours after experimental infection of freshly excised human corneas. We also found viral RNA only in a very limited percentage of donors with positive nasopharyngeal PCR. The low rate of positivity in donors diagnosed with COVID-19 calls into question the utility of donor selection algorithms.
TRIAL REGISTRATION
Agence de la Biomédecine, PFS-20-011 https://www.agence-biomedecine.fr/.
Identifiants
pubmed: 35231027
doi: 10.1371/journal.pmed.1003922
pii: PMEDICINE-D-21-02421
pmc: PMC8887728
doi:
Substances chimiques
Culture Media
0
RNA, Viral
0
Receptors, Coronavirus
0
Cathepsins
EC 3.4.-
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Serine Endopeptidases
EC 3.4.21.-
TMPRSS2 protein, human
EC 3.4.21.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003922Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Cell Mol Immunol. 2021 Feb;18(2):318-327
pubmed: 33408342
J Clin Virol. 2021 Aug;141:104878
pubmed: 34134035
Lancet Infect Dis. 2020 Apr;20(4):411-412
pubmed: 32105638
Br J Ophthalmol. 2022 Mar;106(3):312-318
pubmed: 33243832
J Med Virol. 2020 Oct;92(10):2081-2086
pubmed: 32374427
Cornea. 2020 Dec;39(12):1556-1562
pubmed: 32826650
Curr Ophthalmol Rep. 2021;9(3):77-82
pubmed: 34377601
Ocul Surf. 2021 Jan;19:322-329
pubmed: 33176215
JAMA Ophthalmol. 2021 Apr 1;139(4):383-388
pubmed: 33475692
Cell Rep. 2020 Nov 3;33(5):108339
pubmed: 33147451
Eye (Lond). 2020 Jul;34(7):1206-1211
pubmed: 32424327
JAMA Ophthalmol. 2016 Feb;134(2):167-73
pubmed: 26633035
Cornea. 2021 Mar 1;40(3):342-347
pubmed: 32604196
Cell. 2020 Nov 12;183(4):1043-1057.e15
pubmed: 32970989
J Strength Cond Res. 2013 Aug;27(8):2323-37
pubmed: 23880657
Nat Commun. 2020 Sep 2;11(1):4400
pubmed: 32879306
N Engl J Med. 1979 Mar 15;300(11):603-4
pubmed: 368632
Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1757-61
pubmed: 11431439
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Lancet. 2020 Feb 22;395(10224):e39
pubmed: 32035510
Exp Eye Res. 2003 Oct;77(4):515-24
pubmed: 12957150
Ocul Surf. 2021 Jan;19:190-200
pubmed: 32502616
Exp Eye Res. 2015 May;134:39-46
pubmed: 25795052
Ocul Surf. 2020 Oct;18(4):537-544
pubmed: 32544566
SSRN. 2020 Jul 15;:3650574
pubmed: 32742243
Cornea. 1997 Mar;16(2):132-7
pubmed: 9071524
Mol Syst Biol. 2020 Jul;16(7):e9610
pubmed: 32715618
Eye (Lond). 2004 May;18(5):519-24
pubmed: 15131685
Nature. 2015 May 21;521(7552):274-6
pubmed: 25993940
PLoS Comput Biol. 2020 Dec 8;16(12):e1008461
pubmed: 33290397
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Mol Cell Proteomics. 2020 Sep;19(9):1503-1522
pubmed: 32591346
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
Ophthalmology. 2021 Apr;128(4):494-503
pubmed: 32882309
Graefes Arch Clin Exp Ophthalmol. 2003 Nov;241(11):934-42
pubmed: 14586591
Diagnostics (Basel). 2021 Feb 21;11(2):
pubmed: 33670020
Lancet Microbe. 2020 May;1(1):e14-e23
pubmed: 32835326